To identify new susceptibility loci for psoriasis, we undertook a genome-wide association study of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls. We identified associations at eight previously unreported genomic loci. Seven loci harbored genes with recognized immune functions (IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFKBIA and TYK2). These associations were replicated in 9,079 European samples (six loci with a combined P < 5 × 10 −8 and two loci with a combined P < 5 × 10 −7 ). We also report compelling evidence for an interaction between the HLA-C and ERAP1 loci (combined P = 6.95 × 10 −6 ). ERAP1 plays an important role in MHC class I peptide processing. ERAP1 variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele. Our findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis.
Psoriasis is a common, chronic skin disease with a complex genetic and environmental etiology which is characterized by epidermal hyper-proliferation, vascular remodeling and inflammation 1 . Prior linkage and association studies have unambiguously identified a disease susceptibility locus of large effect (termed PSORS1) spanning ~300 kb of the major histocompatibility complex (MHC) class I region on chromosome 6p21 (ref. 2) . Large-scale resequencing has established HLA-C as the most likely PSORS1 candidate gene 3 .
Genome-wide association studies (GWAS) and analysis of candidate genomic regions have captured eight non-MHC loci which highlight three pathways of considerable biological relevance to psoriasis pathogenesis [4] [5] [6] [7] [8] [9] . These are NF-κB-regulated signaling, mechanisms of T-cell (particularly Th17) differentiation, and perturbation of the epidermal barrier. To identify additional risk variants, we performed a GWAS as a component of the Wellcome Trust Case Control Consortium 2 (WTCCC2), powered by the inclusion of a substantially larger number of discovery samples as compared to previous psoriasis GWAS. We undertook replication of interesting findings in multiple cohorts drawn from across Europe.
Subjects for the GWAS discovery set were recruited from the UK and Ireland and were of self-reported European ancestry (Supplementary Table 1 ). Individuals with psoriasis (cases) were genotyped on the Illumina Human660W-Quad, and controls were genotyped on the Illumina custom Human1.2M-Duo (Supplementary Note), with a primary analysis performed on the overlapping set of SNPs. We performed stringent data quality control procedures (Online Methods), resulting in a GWAS dataset comprising 2,178 individuals with psoriasis and 5,175 controls genotyped at 535,475 SNPs. Principal components analysis of the study data showed the first principal component stratified individuals by population origin (Supplementary Fig. 1b) . We performed single SNP analysis using score tests under a logistic regression model which assumed multiplicative effects, including the first principal component as a covariate and we accounted for uncertainty in genotype calls as implemented in SNPTEST (see URLs). After removal of known and replicated psoriasis association loci, the overdispersion factor 10 of association test statistics (λ GC ) was 1.045 ( Supplementary Fig. 1c) .
In Table 1 , we show evidence of association in our GWAS data at all other previously reported psoriasis disease risk SNPs. Odds ratios (OR) outside the HLA region range from 1.12 to 1.49, highlighting substantial power to detect susceptibility loci of small effect. As expected, SNPs within the chromosome 6p21 region showed strong evidence for association with psoriasis (most significant SNP rs10484554, P = 4 × 10 −214 , OR = 4.66, 95% CI 4.23-5.13), which extended across a broad region surrounding the class I MHC that includes the established risk locus at HLA-C. Comparison of disease models showed a strong departure from the multiplicative model (P = 1.95 × 10 −8 ). ORs for heterozygotes and homozygotes were 5.41 (95% CI 4.81-6.08) and 10.61 (95% CI 7.86-14.33), respectively. Although not exact, this is comparable to a dominant model, which is in keeping with previous observations 11 .
We identified 16 previously unreported loci for further investigation ( Fig. 1) , including all regions with P < 10 −7 and further loci which yielded a P ≤ 10 −4 that contained strong biological candidate genes 1 . Seven independent replication datasets of cases and controls were drawn from across Europe (including 10,060 individuals prior A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 9 8 6 VOLUME 42 | NUMBER 11 | NOVEMBER 2010 Nature GeNetics l e t t e r S to quality control filtering). The most strongly associated SNP or a surrogate for each of the 16 previously unreported loci was genotyped using the Sequenom iPlex platform ( Table 2 and Supplementary  Tables 2 and 3) .
Eight regions showed strong evidence of association and independent replication (analyzed using fixed-effects methods); six regions had P < 5 × 10 −8 and two had P < 5 × 10 −7 in the combined GWAS and replication dataset, with OR estimates in the replication sample ranging from 1.12 (chromosome 2p16) to 1.40 (chromosome 19p13). See Table 2 and Figure 2 for the regional signal plots. Closer analysis (Supplementary Note) of the original signals at the 2p16, 6q21 and 19p13 loci revealed multiple statistically independent SNP associations. Two of these loci were tested and confirmed in our replication study ( Table 2) . Full details are given in Supplementary Table 4 .
Where there were signals at two SNPs within a locus, it was difficult from our data to rule out the possibility that the pattern of association was generated by a single untyped SNP. Regardless of this, we note that under a multiplicative model, the effect of carrying an additional copy of each of the risk alleles at 2p16, 6q21 and 19p13 is 1.40 (95% CI 1.25-1.56), 1.66 (95% CI 1.44-1.92) and 1.52 (95% CI 1.31-1.75), respectively. One important consequence of the potential allelic heterogeneity is that the overall genetic effect at each locus is larger than that associated with the single SNP with the lowest P value.
Although most of the new disease-associated intervals (as defined by recombination hotspots) listed in Table 2 span multiple transcripts, all but one contain at least one immune-related gene. These genes are strong biological candidates for disease association, and it is notable that they collectively cluster into a limited number of pathways with recognized roles in innate and adaptive immunity. For instance, ERAP1 in the chromosome 5q15 associated region encodes an amino peptidase which regulates the quality of peptides bound to MHC class I molecules, such as that encoded by HLA-C (ref. 12). rs30187 within this interval is also significantly associated with ankylosing spondylitis 13 . Given the established link between psoriasis and the development of spondylo-arthropathy 14 , the finding of an association at the ERAP1 locus in both conditions is noteworthy, particularly as the coding SNP rs30187 also generated a very significant P value in our GWAS (P = 1.5 × 10 −9 , OR = 1.27, 95% CI 1.13-1.31). Conditional analyses in our association data did not distinguish significantly between our top SNP, rs27524, and the coding variant rs30187.
The chromosome 6q21 region spans four known genes (Fig. 2) . Of these genes, TRAF3IP2 encodes ACT1, an adaptor protein essential for IL17-dependent NF-κB activation and Th17-mediated inflammatory responses 15 . Remarkably, genes participating in NF-κB and IL17-mediated signaling are also found in three further disease susceptibility regions identified by this study. NFKBIA, the only gene lying within the associated region at 14q13, encodes a key inhibitory protein that inactivates NF-κB dimers in the absence of inflammatory stimuli 16 . Likewise, REL, which maps to the associated region on chromosome 2p16, encodes one of four subunits found in NF-κB dimers and has recently been implicated in risk for rheumatoid arthritis 16, 17 . Finally, the interval on chromosome 19p13 includes TYK2, which encodes a kinase promoting IL17 transcription through STAT3 phosphorylation 18 . Common and low-frequency variants of TYK2 confer risk in multiple autoimmune diseases, namely type 1 diabetes and systemic lupus erythematosus 19 .
It is noteworthy that TYK2 also regulates type I and type III interferon (IFN) signaling 20 , suggesting that innate IFN-activating anti-microbial response pathways may contribute to initiation or maintenance of disease progression. This would be consistent with our observation of disease-associated variants in the proximity of IL28RA, which encodes a type III IFN receptor subunit 21 . Pathogenic involvement of IFN signaling pathways is also supported by the association signal detected on chromosome 2q24. In this instance, the associated region encompasses the IFIH1, FAP and GCA genes together with part of KCNH7, as shown in Figure 2 . Of these genes, IFIH1 encodes an innate receptor which triggers type I IFN in response to microbial infection 22 , and both rare and common IFIH1 variants are associated with type 1 diabetes 23 . rs1990760 (minor allele frequency = 0.38) has a strong signal in our sample and in type 1 diabetes, but the correlation between this SNP and rs17716942 was low (r 2 = 0.3). Further resequencing of IFIH1 will be required to determine the properties of rare variations in relation to psoriasis risk.
Given the presence of many signals within a small number of pathways, we looked for statistical interactions (Online Methods) between the top SNPs in each of the 17 known and confirmed newly associated regions shown in Tables 1 and 2 and fitting a dominant model at the HLA-C SNP rs10484554. One pair of SNPs (rs10484554 at HLA-C and Regions which have been shown previously to be associated with psoriasis and which replicated in this study are highlighted in green, as described in l e t t e r S rs27524 at ERAP1) generated strong evidence for interaction in the discovery, replication and combined data (discovery P = 2.45 × 10 −5 , replication P = 0.027, combined P = 6.95 × 10 −6 ) (Supplementary Table 5 ). Figure 3 shows that when stratified by genotypes at the two loci, the ERAP1 SNP only has an effect in individuals carrying at least one copy of the risk allele at rs10484554. Very few convincing examples of interactions between complex disease loci have been reported in humans [24] [25] [26] , perhaps because the power to detect these interactions is limited unless the causal SNPs or very good surrogates have been typed 27 . The finding that variation at the ERAP1 locus is only associated with disease in individuals carrying the HLA-C risk allele is particularly interesting biologically because of the role of ERAP1 in class I peptide presentation. It is also noteworthy that the odds ratio for rs27524 is 1.43 (95% CI 1.21-1.69) in the HLA-C-positive subgroup as compared to the estimate of 1.27 (95% CI 1.18-1.38) from the GWAS of the entire dataset (in the replication data these estimates were 1.23 (1.09-1.39) and 1.13 (94% CI 1.05-1.22), respectively). Were this phenomenon to be more widespread, it would affect the proportion of broad-sense heritability explained by the GWAS findings. GLP-1, FDX1L, RAVER1, ICAM3, TKY2 , CDC37, PDE4A, KEAP1 and S1PR5. Evidence for association at loci reported in this study. Chr., chromosome; P scan , scan stage P; P repl , replication stage P; P comb , combined P. l e t t e r S Next, we looked systematically across the genome for other loci which might only have an effect on one or other of the HLA-C risk backgrounds. We divided individuals in our discovery study into two groups, depending on whether they carried zero copies ('HLA-C negative' individuals included 831 cases and 3,985 controls) or one or two copies ('HLA-C positive' individuals included 1,347 cases and 1,190 controls) of the risk allele at rs10484554, the index SNP for the HLA-C locus, and we undertook separate GWAS in each group ( Supplementary Fig. 2 and Supplementary Table 6) .
Four other loci generated evidence for association in the GWAS of HLA-C-positive individuals. One of these, rs17695937, near ZAP70, also displayed a clear signal in the replication data, generating a combined P = 2.37 × 10 −7 . Several of the other loci also warrant further investigation (Supplementary Fig. 2 ). The identification of risk variation at ZAP70 together with ERAP1 in individuals with HLA-C risk alleles provides further genetic evidence that psoriasis may in part be caused by dysregulation of HLA-restricted CD8 T cells. ZAP70 is a tyrosine kinase that binds to the T-cell receptor-associated chain, CD3-ζ (CD247), following the TCR engagement of MHC-peptide complexes and is critical for setting the response threshold that in turn governs the T-cell selection events which purge the T-cell compartment of autoreactivity 28 . Finally, although we followed up several SNPs from the HLA-negative GWAS, none of them replicated (Supplementary Table 6 ).
We undertook additional analyses of the relationship between the known classical HLA risk allele, Cw*0602, and typed SNPs. Based on molecular typing in a subset of 725 of the 1958 British Birth Cohort (58C) individuals, the correlation between Cw*0602 genotypes (that is, 0, 1 or 2 copies of Cw*0602) and our top SNP, rs10484554, was r 2 = 0.7. We imputed the HLA-C genotypes from our SNP data 29 (Online Methods). Association testing with these imputed genotypes showed a stronger signal for the classical allele than for any single SNP, yet conditional analyses have not been definitive in ruling out either variant as the primary source of the signal (Supplementary Note). We re-examined the HLA-C-ERAP1 interaction in an attempt to determine whether it was driven by the top SNP (rs10484554) or the classical allele at HLA-C, and likewise, whether the top SNP (rs27524) or the previously reported coding SNP (rs30187) at ERAP1 was more closely involved. Although evidence for interaction existed for all four pairs of markers (Supplementary Table 7) , the dominant model at the HLA Cw*0602 allele with an interaction at the ERAP1 SNP rs27524 best fits the GWAS data. Conditional analyses were not definitive in ruling out either variant at either site as the primary source of the interaction signal.
Collectively, the candidate genes identified in this study are relevant to the question of whether psoriasis is primarily an epidermal or an immune dysfunction disorder. The present data provide evidence for an integrated model for the pathogenesis of psoriasis that combines skin barrier function (for example, variants in LCE3B and LCE3C), innate immune pathogen sensing focused on NF-κB and IFN signaling (for example, in NFKBIA, REL, TYK2, IFIH1 and IL28RA), and adaptive immunity involving CD8 T lymphocytes (ERAP1 and ZAP70) and Th17 cell responses (for example, in TRAF3IP2, TYK2 and IL23R). Fine mapping, functional characterization and meta-analyses in additional psoriasis cohorts can now determine the detailed molecular consequences of genetic variation on these pathways. Finally, this study also provides one of the first compelling examples of an interaction between two GWAS loci, and the success of our separate GWAS in HLA-C-positive individuals suggests that similar analyses might be valuable in other autoimmune diseases.
URLs. SNPTEST, http://www.stats.ox.ac.uk/~marchini/software/ gwas/snptest.html; WTCCC2, http://www.wtccc.org.uk/ccc2/; access to the data access committee, http://www.ebi.ac.uk/ega/.
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Samples. Cases. A total of 6,523 samples were assembled for this investigation, of which 2,735 were processed for the GWAS discovery set and 3,788 of which were processed for the replication set. For all samples, psoriasis was defined as psoriasis vulgaris (chronic plaque type psoriasis), the commonest manifestation of the disease. A total of 2,178 DNA samples from unrelated individuals of European ancestry, recruited from five centers in England, Scotland and Ireland were included in the GWAS discovery set, having passed pre-and postgenotyping control filters (see below). Phenotypic data and blood samples were collected after research ethics approval was received from each participating institution and after subjects had given written, informed consent. The replication set of DNA was derived from individuals with psoriasis recruited in several European countries (Austria, Germany, Italy, Netherlands, Spain, Sweden and the UK) after research ethics approval and written informed consent was given. In total, 3,174 DNA samples passed quality control for replication.
Controls.
A total of 10,639 control individuals passed the quality control filters (see below). 5,175 individuals from the WTCCC2 common control set were used in the discovery GWAS. This included 2,501 healthy blood donors from the United Kingdom Blood Service (UKBS) collection and 2,674 individuals from the 1958 Birth Cohort (58C) dataset 27 . 5,464 individuals were used in the replication dataset, including 2,717 from the People of the British Isles (PoBI) collection. The remaining controls were taken from six other European populations selected to match the case individuals. These collections have been described elsewhere (Supplementary Table 1) .
Details of DNA sample preparation and genotyping are given in the Supplementary Note. Quality control. Full details of quality control procedures are given in the Supplementary Note.
Samples. We used a recently developed Bayesian clustering approach to infer and exclude outlying individuals on the basis of call rate, heterozygosity, relatedness and ancestry 30 and for an additional artifact which led to spurious associations, where for some samples SNP intensities in one channel were systematically higher than in the other (Supplementary Fig. 1a) . We also excluded one of each pair of related individuals as identified by a hidden Markov model.
SNPs.
SNPs were excluded if the Fisher information for the allele frequency was not close to unity or if the minor allele frequency was very low (defined as <0.01%) or for extreme departures from Hardy-Weinberg equilibrium (except in the MHC) or if they showed a strong plate effect. Cluster plots of SNPs showing putative associations were inspected manually (Supplementary Fig. 3 ).
The quality control measures excluded 444 cases and 492 controls and 9.8% of the SNPs. Of the 2,178 case samples which passed quality control, 345 had self-reported Irish ancestry (Supplementary Table 8 ).
Statistical methods. We performed principal component analysis on a subset of 205,842 post-quality-control SNPs (none from the MHC) selected so as to minimize the contribution from regions of extensive strong LD and to ensure that only genome-wide effects were detected. Principal component scores were computed for the combined dataset of post-exclusion case and control samples. After inspection, the first principal component acted to differentiate individuals from the UK from those from Ireland (Supplementary Fig. 1b) , suggesting that the major determinant of the variance in genome-wide patterns of diversity between sample individuals was due to differences in ancestry. To guard against possible artifacts due to population structure, we repeated the primary association analysis excluding the Irish cases. Reassuringly, this yielded comparable association signals after allowing for the reduction in sample size (data not shown). As no further principal components driven by genome-wide patterns exhibited significant differences between cases and controls, we used only the first principal component to control for population stratification in subsequent analyses.
We used a logistic regression model with case or control status as the response variable, the first principal component as a covariate and the genotype at a particular SNP as the explanatory variable. Genome-wide association tests were carried out at each SNP with uncertainty in genotype calls modeled using missing data likelihoods as implemented in SNPTEST. Unless otherwise stated, we assumed that the change in the odds of case status due to each copy of the allele was multiplicative. To investigate patterns of association between SNPs, for example to look for interactions or secondary signals, we used the statistical package R 31 .
It has become standard practice in GWAS to refer to the odds ratio associated with a particular allele or haplotype, which we estimate as e β , where β is the maximum likelihood estimate of the coefficient describing the effect of each predictor on the response in the assumed model. We note however that, as is true of this study and many others, where the controls are taken at random from the population without reference to disease status, β is actually the log of the relative risk and not the log of the odds ratio 32 .
Imputation was performed using IMPUTE2 (ref. 33) , which adopts a two-stage approach using both a haploid reference panel and a diploid reference panel. We used two methods to investigate possible secondary signals within GWAS association regions, standard frequentist conditional analyses and the program GENECLUSTER 34 , which adopts a Bayesian approach to look for primary and secondary association signals at known and putative SNPs. See Supplementary Note for full details and for additional pre-imputation SNP quality control.
We used standard 'fixed-effect' meta-analysis techniques to analyze the replication data. Specifically, in each population, we fitted a logistic regression model for case or control status with no covariates at each SNP with a single parameter for the genetic effect (a multiplicative effect on the risk scale and an additive efect on the log-odds scale). We then assumed a fixed underlying genetic effect common to all populations for the SNP, which we estimated by combining the effect estimates across populations, weighting by the precision of the estimate within each population. P values, effect size estimates and confidence individuals for each population and combined across populations are shown in Supplementary Table 2 and Supplementary Figure 4 . As is typical for GWAS replication studies which type a small number of SNPs, testing for possible substructure within populations was not possible. Our replication results involved averaging across separate results for seven populations. This provided robustness against false positives due to substructure in some populations, and it is encouraging that most or all replication populations typically exhibited evidence for the signal. We confirmed the power of this replication cohort by genotyping rs4085613 and rs4112788, which tag the known LCE3B and LCE3C psoriasis risk locus 6, 9 , where we observed replication P values of 2.33 × 10 −15 and 4.44 × 10 −16 , respectively.
To look for interactions between associated loci, we considered all pairs of index SNPs listed in Tables 1 and 2 , and for each pair, we compared two logistic regression models. In the first (null) model, a separate parameter for each SNP specified the multiplicative increase in the odds of disease with each additional copy of the risk allele for that SNP. We compared this, using a likelihood ratio test, to a model for interaction in which there is a third parameter which modifies the effect associated with carrying risk alleles at both SNPs. There are many different ways to model both the marginal effects at each SNP and their joint effect 35 , and so there are many approaches to search for interactions. The procedure we adopted is perhaps the simplest (multiplicative model marginally at each SNP and a single additional parameter for multiplicative interactions). Having identified the interaction between the HLA-C and ERAP1 loci, we examined the nature of the effect and observed that it takes the simple, and easily interpretable, form in which additional copies of the index SNP at ERAP1 only affect disease risk in HLA-C-positive individuals. To test for interactions between SNPs in the replication data, we included a categorical covariate indicating population membership in the logistic regression model. We used this framework to compare two models through a likelihood ratio test, which included or excluded a term for the interaction between the two SNPs.
HLA imputation. Imputation of classical HLA genotypes was performed using previously published statistical methodology 29 and a reference panel of over 1,500 samples with classical HLA and SNP genotype data from the 1958 Birth Cohort and the International HapMap Project 36 . When predicting whether an individual carries one or more copies of the HLA Cw*0602 allele, the primary risk allele for psoriasis, we estimated the false positive rate to be 1% (no call threshold) and the false negative rate to be less than 1%. In the replication study, four SNPs were typed in the HLA region (rs10484554, rs3906272, rs12111032 and rs2243868), two of which (rs12111032 and rs2243868) form a near perfect (false positive rate < 1%) haplotype tag for Cw*0602 (alleles A and G on the plus strand, respectively). Imputations were performed by phasing the four SNPs with PHASE 37 and assuming the AG haplotype to be a perfect tag. From the independent validation study, we estimated the false positive rate of this approach to be 9% (no call threshold), with the decrease in accuracy resulting from an uncertainty in phasing. As a check, we then applied the imputation approach we used in the replication data to the GWAS samples. Comparison of the imputations made using the four SNPs to those made from the full GWAS data show 1.4% of Cw*0602 presence or absence predictions to be discrepant.
Data availability.
A list of the SNPs in the discovery scan with P < 10 −4 is available in Supplementary Table 9 . Researchers can gain access to the data by applying to the data access committee (see URLs).
